Thema: GB00BN7SWP63
GSK, GB00BN7SWP63
GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung - Foto: THN
GSK stock: Specialty medicines offset weaker vaccines in Q3
GSK's specialty medicines continued to drive growth as vaccine sales weakened in the third quarter. The company kept its 2026 outlook.
ad-hoc-news.de, heute 16:34 Uhr
GSK, GB00BN7SWP63
GSK reports third-quarter growth and declares 17 pence dividend ...
GSK reported GBP 8.89 billion in third-quarter sales, up 5 percent at constant currency. The company declared a 17 pence dividend per GSK stock.
ad-hoc-news.de, 28.10.26 10:25 Uhr
GSK, GB00BN7SWP63
Barclays sets GBp 1,800.00 target for GSK stock
GSK's Q2 revenue reached GBP 8.41 billion in its report. GSK stock costs EUR 22.91 on October 27, 2026, up 0.35 percent versus the Xetra close.
ad-hoc-news.de, 27.10.26 17:07 Uhr
GSK, GB00BN7SWP63
GSK schedules third-quarter results. GSK stock stands at ...
GSK's October 26 cancer data showed a 76 percent response rate. GSK stock costs EUR 22.87 on October 27, 2026, 0.09 percent above Xetra close.
ad-hoc-news.de, 27.10.26 10:52 Uhr
GSK, GB00BN7SWP63
Jefferies issues a GBp 2,500.00 target for GSK stock
GSK expects third-quarter results on October 28, 2026. GSK stock costs EUR 22.91 on October 26, 2026, up 1.33 percent versus the Xetra close.
ad-hoc-news.de, 26.10.26 16:54 Uhr
GSK, GB00BN7SWP63
GSK wins Hibsago approval as analysts set target for GSK ...
Hibsago won US approval on October 21, 2026, adding a hepatitis B option. GSK stock costs EUR 22.72 on October 26, 2026, 0.49 percent above Xetra.
ad-hoc-news.de, 26.10.26 09:58 Uhr
GSK, GB00BN7SWP63
GSK reports 76 percent complete responses as GSK stock trades ...
